Platelet Reactivity and MES During CEA
Platelet Reactivity Testing in Association With Perioperative Microembolic Signals During Carotid Endarterectomy
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584CX
- UMC Utrecht
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Al patients undergoing elective carotid endarterectomy
Exclusion Criteria:
- Patients requiring a blood transfusion prior to surgery
- Patients with an inappropriate temporal bone window for transcranial Doppler (TCD)
- Patients on vitamin K antagonists or antiplatelet treatment other then aspirin
- Patients with an artificial cardiac valve
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Carotid endarterectomy (CEA)
Patients undergoing carotid endarterectomy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microembolic signals (MES)
Time Frame: During and 1 hour following carotid endarterectomy (CEA)
|
Microembolic signals detected by transcranial duplex (TCD)
|
During and 1 hour following carotid endarterectomy (CEA)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ischemic stroke
Time Frame: within 30 days postoperative
|
within 30 days postoperative
|
|
|
Asymptomatic perioperative myocardial injury
Time Frame: 3 days postoperative
|
Troponin elevation > 0.1 ng/ml
|
3 days postoperative
|
|
Myocardial infarction
Time Frame: Within 30 days postoperative
|
Within 30 days postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arterial Occlusive Diseases
- Carotid Artery Diseases
- Stroke
- Myocardial Infarction
- Infarction
- Ischemic Stroke
- Carotid Stenosis
Other Study ID Numbers
Other Study ID Numbers
- NL33061.051.10
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.